Kenvue’s SWOT analysis: stock faces headwinds amid strategic shifts

Kenvue Inc. (KVUE) reported a 4.2% organic sales decline in Q2 2025, revising its full-year outlook to low-single-digit declines, exacerbated by broad underperformance and significant investor concern over its key Tylenol brand following reports of a potential link between prenatal acetaminophen use and neurodevelopmental disorders. In response, the company has initiated a strategic review, appointed an interim CEO, and is implementing an "Extraordinary Powers" strategy to streamline operations and improve execution, while also attracting activist investor interest. Despite these challenges, KVUE maintains strong gross margins and a solid financial foundation, with operational improvements, particularly in the Skin Health & Beauty segment, offering potential for significant value creation.

Analysis

Kenvue Inc. is confronting a period of significant operational and reputational challenge following its spin-off. The company reported a 4.2% year-over-year decline in organic sales for Q2 2025, prompting a guidance revision for the full year from 2-4% growth to a low-single-digit decline. This weakness was systemic, with sales falling across all three segments: Self Care (-5.9%), Skin Health & Beauty (-3.7%), and Essential Health (-2.4%). Compounding these operational issues is a major overhang from its Tylenol brand, which constitutes approximately 15% of U.S. sales, as an upcoming Department of Health & Human Services study has flagged a potential link between prenatal acetaminophen use and neurodevelopmental disorders. In response, Kenvue has appointed an interim CEO, initiated a strategic review, and attracted the attention of activist investors including Starboard Value and Third Point, signaling pressure for change. Despite these headwinds, the company maintains a strong financial profile, characterized by a 58.15% gross margin, a 4.53% dividend yield, and a healthy Altman Z-Score of 4.04. Valuation appears potentially attractive, with a forward P/E of 19.7 and a PEG ratio of 0.96, suggesting the market may be undervaluing the potential for a successful turnaround, particularly in the underperforming Skin Health & Beauty segment where analysts see substantial value creation opportunities.

Key Decisions for Investors

• Investors must weigh the significant headline risk and potential financial impact from the Tylenol controversy against the compelling valuation case, highlighted by a PEG ratio of 0.96 and a 4.53% dividend yield.
• Monitor for any official statements from the FDA or HHS regarding acetaminophen, as this represents the primary near-term risk catalyst, and track consumption data for brands like Neutrogena and Aveeno for early signs of a turnaround in the Skin Health & Beauty segment.
• The presence of several activist investors suggests an increased likelihood of aggressive strategic actions, such as divestitures or major cost restructuring, which could unlock value independently of organic growth improvements.
• Consider a position for a long-term, value-oriented portfolio with a high risk tolerance, as the investment thesis hinges on management successfully executing its 'Extraordinary Powers' strategy and navigating the ongoing regulatory scrutiny.